Compare Johnson & Johnson (JNJ) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Tapestry, Inc. — how do they compare? Johnson & Johnson trades at $261.04 (market cap $618.09B), while Tapestry, Inc. trades at $116.61 (market cap $23.09B). The key difference: Johnson & Johnson is far larger — about 26.8× Tapestry, Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Tapestry, Inc. for 70 Days on average.
| JNJ | TPR | |
|---|---|---|
Market Cap | $618.09B | $23.09B |
Volume | 6,050,983 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $164.78 |
52-Week Low | $186.00 | $98.81 |
Typical Hold Time | 129 Days | 70 Days |
Enterprise Value | $646.37B | $25.89B |
Dividend Yield | 2.09% | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
TPR trades at $116.26, up 2.53% today, with a bearish technical signal but strong analyst consensus. Recent earnings beats and a high ROE of 197.14% highlight operational strength, though net income margin fell sharply in 2025. The stock is supported by a $174.64 consensus price target and positive news on international growth, but faces risks from tariffs and Kate Spade execution challenges.
Outlook remains positive with 73% buy ratings and projected revenue growth to $8.0B in 2026. Key opportunities include margin expansion and Coach brand momentum, while risks involve volatile cash flows, high debt, and competitive pressures. The current price offers a 50% upside to the consensus target, but investors should monitor earnings delivery and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
